On 19 November 2014, orphan designation (EU/3/14/1365) was granted by the European Commission to FGK Representative Service GmbH, Germany, for recombinant human pentraxin-2 for the treatment of primary myelofibrosis.

Key facts

Active substance
Recombinant human pentraxin-2
Disease / condition
Treatment of post-polycythaemia vera myelofibrosis
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

FGK Representative Service GmbH
Heimeranstrasse 35
80339 Munich
Tel. +49 89 893 119 22
Fax +49 89 893 119 20

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating